

# Toxicological Profile for Chlorophenols

June 2022



# DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

atich Margh

Patrick N. Breysse, Ph.D., CIH Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention

hin M Gel

Christopher M. Reh, Ph.D. Associate Director Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention

#### \*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

# **VERSION HISTORY**

Date	Description
June 2022	Final toxicological profile released
July 2021	Draft for public comment toxicological profile released
July 1999	Final toxicological profile released

## **CONTRIBUTORS & REVIEWERS**

### CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D. (Lead) Custodio Muianga, M.P.H., Ph.D., CHMM

ATSDR, Office of Innovation and Analytics, Toxicology Section, Atlanta, GA Heather Carlson-Lynch, M.S., D.A.B.T. Claire Heit, Ph.D. Mario Citra, Ph.D. SRC, Inc., North Syracuse, NY

## REVIEWERS

#### Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

#### Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Water.

## PEER REVIEWERS

- 1. Matt Simcik, Ph.D.; Professor, Division of Environmental Health Sciences; School of Public Health; University of Minnesota; Minneapolis, Minnesota
- 2. Ghulam Ahmad Shakeel Ansari, Ph.D.; Professor, Department of Pathology; The University of Texas Medical Branch; Galveston, Texas
- 3. Russell C. Cattley; Tyler & Frances Young Professor, V.M.D., Ph.D., DACVP; Head, Department of Pathobiology; College of Veterinary Medicine; Auburn University, Alabama

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

# CONTENTS

LIST OF FIGURES	DISCLAIMER	ii
CONTRIBUTORS & REVIEWERS		
CONTENTS       vii         LIST OF FIGURES       ix         LIST OF TABLES       xi         CHAPTER 1. RELEVANCE TO PUBLIC HEALTH       1         1.1       OVERVIEW AND U.S. EXPOSURES       1         1.2       SUMMARY OF HEALTH EFFECTS.       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS.       19         2.1       INTRODUCTION.       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEATIC       91         2.10       DERNAL       97         2.11       DERNAL       97         2.12       OCULAR       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       126         2.18       OT	VERSION HISTORY	v
CONTENTS       vii         LIST OF FIGURES       ix         LIST OF TABLES       xi         CHAPTER 1. RELEVANCE TO PUBLIC HEALTH       1         1.1       OVERVIEW AND U.S. EXPOSURES       1         1.2       SUMMARY OF HEALTH EFFECTS.       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS.       19         2.1       INTRODUCTION.       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEATIC       91         2.10       DERNAL       97         2.11       DERNAL       97         2.12       OCULAR       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       126         2.18       OT	CONTRIBUTORS & REVIEWERS	vi
LIST OF FIGURES		
LIST OF TABLES       xi         CHAPTER 1. RELEVANCE TO PUBLIC HEALTH       1         1.1       OVERVIEW AND U.S. EXPOSURES       1         1.2       SUMMARY OF HEALTH EFFECTS       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       PHATIC       91         2.10       DERNAL       97         2.11       DERNAL       97         2.12       OCULAR       100         2.13       BNDOCRINE       101         2.14       IMMUNOLOGICAL       107         2.15       NEUROLOGICAL       103         2.10       RENAL       107         2.11       DERMAL       107         2.12       OCULAR       101         2.14 </td <td></td> <td></td>		
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH		
1.1       OVERVIEW AND U.S. EXPOSURES       1         1.2       SUMMARY OF HEALTH EFFECTS       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.10       RENAL       97         2.11       DERMAL       97         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       CRPRODUCTIVE       111         2.17       DEVELOPMENTAL       123		
1.1       OVERVIEW AND U.S. EXPOSURES       1         1.2       SUMMARY OF HEALTH EFFECTS       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.10       RENAL       97         2.11       DERMAL       97         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       CRPRODUCTIVE       111         2.17       DEVELOPMENTAL       123	CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.2       SUMMARY OF HEALTH EFFECTS.       2         1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       101         2.14       IMMUNOLOGICAL       101         2.15       NEUROLOGICAL       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       101         2.14       IMUNOLOGICAL       103         2.15       NEUROLOGICAL       101         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123		
1.3       MINIMAL RISK LEVELS (MRLs)       8         CHAPTER 2. HEALTH EFFECTS.       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         7.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       DERMAL       97         2.11       DERMAL       97         2.12       OCULAR       103         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.19       CANCER       123         2.19       CANCER       145         3.1.1       Absorption       145         3.1.1<		
CHAPTER 2. HEALTH EFFECTS       19         2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CADIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       100         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       111         2.17       DEVELOPMENTAL       127         2.19       CANCER       123         2.19       CANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         3.1       TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL		
2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       101         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.10       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.3       Metabolism       <		0
2.1       INTRODUCTION       19         2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.19       CANCER       123         3.10       CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL         INTERACTIONS       145         3.1.1       Absorption       145	CHAPTER 2. HEALTH EFFECTS	19
2.2       DEATH       75         2.3       BODY WEIGHT       80         2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       INTERACTIONS         1.14       IAbsorption       145         3.1.1       Absorption       145         3.1.2       Distribution </td <td></td> <td></td>		
2.3       BODY WEIGHT		
2.4       RESPIRATORY       82         2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.3       Metabolism       148         3.1.4       Absorption       145         3.1.5       Physiologi		
2.5       CARDIOVASCULAR       85         2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       101         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       145         NTERACTIONS       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.3       Metabolism       148         3.1.4       Excretion       151         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models       153         3.1.6       Animal-to-Human Extrapolations       153		
2.6       GASTROINTESTINAL       87         2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       99         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       107         2.16       REPRODUCTIVE       107         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         2.19       CANCER       127         2.20       GENOTOXICITY       133         2.13       CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       145         3.1       TOXICOKINETICS       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.3       Metabolism       148         3.1.4		
2.7       HEMATOLOGICAL       88         2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       97         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       INTERACTIONS         NTERACTIONS       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.4       Excretion       151         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models       153         3.1.6       Animal-to-Human Extrapolations       153         3.1.6       Animal-to-Human Extrapolations <td></td> <td></td>		
2.8       MUSCULOSKELETAL       90         2.9       HEPATIC       91         2.10       RENAL       97         2.11       DERMAL       99         2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       103         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       INTERACTIONS         1.11       Absorption       145         3.1.1       Distribution       145         3.1.2       Distribution       145         3.1.3       Metabolism       148         3.1.4       Excretion       151         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models       153         3.1.6       Animal-to-Human Extrapolations       153         3.1.6       Animal-to-Hum		
2.9       HEPATIC		
2.10       RENAL		
2.11       DERMAL       .99         2.12       OCULAR       .100         2.13       ENDOCRINE       .101         2.14       IMMUNOLOGICAL       .103         2.15       NEUROLOGICAL       .107         2.16       REPRODUCTIVE       .111         2.17       DEVELOPMENTAL       .118         2.19       CANCER       .123         2.19       CANCER       .127         2.20       GENOTOXICITY       .133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       .145         INTERACTIONS       .145         3.1.1       Absorption       .145         3.1.2       Distribution       .147         3.1.3       Metabolism       .148         3.1.4       Excretion       .151         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models       .153         3.1.6       Animal-to-Human Extrapolations       .153         3.1.7       CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE       .154         3.3       BIOMARKERS OF EXPOSURE AND EFFECT       .156         3.3.1       Biomarkers of Exposure       .157         3.3.2       Biomarkers of E		
2.12       OCULAR       100         2.13       ENDOCRINE       101         2.14       IMMUNOLOGICAL       103         2.15       NEUROLOGICAL       107         2.16       REPRODUCTIVE       111         2.17       DEVELOPMENTAL       118         2.18       OTHER NONCANCER       123         2.19       CANCER       123         2.19       CANCER       127         2.20       GENOTOXICITY       133         CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       INTERACTIONS         INTERACTIONS       145         3.1       TOXICOKINETICS         3.1.1       Absorption         3.1.2       Distribution         3.1.3       Metabolism         3.1.4       Excretion         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models         3.1.6       Animal-to-Human Extrapolations         3.1.7       CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE         3.3       BIOMARKERS OF EXPOSURE AND EFFECT         3.3.1       Biomarkers of Exposure         3.3.2       Biomarkers of Exposure		
2.13ENDOCRINE1012.14IMMUNOLOGICAL1032.15NEUROLOGICAL1072.16REPRODUCTIVE1112.17DEVELOPMENTAL1182.18OTHER NONCANCER1232.19CANCER1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONSINTERACTIONS3.1TOXICOKINETICS3.1.1Absorption3.1.2Distribution3.1.3Metabolism3.1.4Excretion3.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models3.1.6Animal-to-Human Extrapolations3.1BIOMARKERS OF EXPOSURE AND EFFECT3.3.1Biomarkers of EXPOSURE AND EFFECT3.3.2Biomarkers of Effect		
2.14IMMUNOLOGICAL1032.15NEUROLOGICAL1072.16REPRODUCTIVE1112.17DEVELOPMENTAL1182.18OTHER NONCANCER1232.19CANCER1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS1453.1TOXICOKINETICS3.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.2Biomarkers of Exposure157		
2.15NEUROLOGICAL1072.16REPRODUCTIVE1112.17DEVELOPMENTAL1182.18OTHER NONCANCER1232.19CANCER1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONSINTERACTIONS1453.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.2Biomarkers of Effect157		
2.16REPRODUCTIVE1112.17DEVELOPMENTAL1182.18OTHER NONCANCER.1232.19CANCER.1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONSINTERACTIONS3.1TOXICOKINETICS3.1.1Absorption453.1.23.1.2Distribution461473.1.3Metabolism483.1.45.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3.1BIOMARKERS OF EXPOSURE AND EFFECT3.2Biomarkers of Exposure3.2Biomarkers of Exposure3.2Biomarkers of Effect		
2.17DEVELOPMENTAL1182.18OTHER NONCANCER1232.19CANCER1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS1453.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.2Biomarkers of Effect157		
2.18OTHER NONCANCER.1232.19CANCER.1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONSINTERACTIONS3.1TOXICOKINETICS3.1.1Absorption453.1.23.1.2Distribution473.1.3Metabolism483.1.4Excretion513.1.57Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models533.1.63.1.6Animal-to-Human Extrapolations3.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.3.3BIOMARKERS OF EXPOSURE AND EFFECT3.3Biomarkers of Exposure3.3Biomarkers of Exposure3.2Biomarkers of Exposure		
2.19CANCER.1272.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS1451453.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.2Biomarkers of Effect157		
2.20GENOTOXICITY133CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONSINTERACTIONS1453.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.2Biomarkers of Effect157		
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL       145         3.1       TOXICOKINETICS       145         3.1.1       Absorption       145         3.1.2       Distribution       147         3.1.3       Metabolism       148         3.1.4       Excretion       151         3.1.5       Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models       153         3.1.6       Animal-to-Human Extrapolations       153         3.2       CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE       154         3.3       BIOMARKERS OF EXPOSURE AND EFFECT       156         3.3.1       Biomarkers of Exposure       157         3.2       Biomarkers of Effect       157	2.19 CANCER	127
INTERACTIONS 145 3.1 TOXICOKINETICS 145 3.1.1 Absorption 145 3.1.2 Distribution 147 3.1.3 Metabolism 147 3.1.4 Excretion 151 3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 153 3.1.6 Animal-to-Human Extrapolations 153 3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 154 3.3 BIOMARKERS OF EXPOSURE AND EFFECT 156 3.3.1 Biomarkers of Exposure 157 3.3.2 Biomarkers of Effect 157	2.20 GENOTOXICITY	133
INTERACTIONS 145 3.1 TOXICOKINETICS 145 3.1.1 Absorption 145 3.1.2 Distribution 147 3.1.3 Metabolism 147 3.1.4 Excretion 151 3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 153 3.1.6 Animal-to-Human Extrapolations 153 3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 154 3.3 BIOMARKERS OF EXPOSURE AND EFFECT 156 3.3.1 Biomarkers of Exposure 157 3.3.2 Biomarkers of Effect 157		
3.1TOXICOKINETICS1453.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157		
3.1.1Absorption1453.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	INTERACTIONS	145
3.1.2Distribution1473.1.3Metabolism1483.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	3.1 TOXICOKINETICS	145
3.1.3Metabolism	3.1.1 Absorption	145
3.1.4Excretion1513.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	3.1.2 Distribution	147
3.1.5Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models1533.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	3.1.3 Metabolism	148
3.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	3.1.4 Excretion	151
3.1.6Animal-to-Human Extrapolations1533.2CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 1543.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157	3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	153
3.2       CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 154         3.3       BIOMARKERS OF EXPOSURE AND EFFECT		
3.3BIOMARKERS OF EXPOSURE AND EFFECT1563.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157		
3.3.1Biomarkers of Exposure1573.3.2Biomarkers of Effect157		
3.3.2 Biomarkers of Effect		
3.4 INTERACTIONS WITH OTHER CHEMICALS	3.4 INTERACTIONS WITH OTHER CHEMICALS	

CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION	
4.1 CHE	MICAL IDENTITY	
4.2 PHYS	SICAL AND CHEMICAL PROPERTIES	159
CHAPTER 5	POTENTIAL FOR HUMAN EXPOSURE	167
	RVIEW	
	DUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	
	roduction	
	nport/Export	
	-FF	
	Disposal	
	EASES TO THE ENVIRONMENT	
	.ir	
	Vater	
	oil	
	RONMENTAL FATE	
	ransport and Partitioning	
	ransformation and Degradation	
	ELS IN THE ENVIRONMENT	
	ir	
	Vater	
	ediment and Soil	
	Other Media	
	ERAL POPULATION EXPOSURE	
	JLATIONS WITH POTENTIALLY HIGH EXPOSURES	
CHAPTER 6	ADEQUACY OF THE DATABASE	219
	RMATION ON HEALTH EFFECTS	
	TIFICATION OF DATA NEEDS	
	OING STUDIES	
CHAPTER 7.1	REGULATIONS AND GUIDELINES	
CHAPTER 8	REFERENCES	230

## APPENDICES

APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR CHLOROPHENOLS	B-1
APPENDIX C.	USER'S GUIDE	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E.	GLOSSARY	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

CHLOROPHENOLS

# LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to 2-Chlorophenol	3
1-2. Health Effects Found in Animals Following Oral Exposure to 4-Chlorophenol	4
1-3. Health Effects Found in Animals Following Oral Exposure to 2,4-Dichlorophenol	5
1-4. Health Effects Found in Animals Following Oral Exposure to 2,4,5-Trichlorophenol	6
1-5. Health Effects Found in Animals Following Oral Exposure to 2,4,6-Trichlorophenol	6
1-6. Health Effects Found in Animals Following Oral Exposure to 2,3,4,6-Tetrachlorophenol	7
1-7. Health Effects Found in Animals Following Oral Exposure to Other Chlorophenols	7
1-8. Summary of Sensitive Targets of 2-Chlorophenol – Oral	11
1-9. Summary of Sensitive Targets of 4-Chlorophenol – Oral	12
1-10. Summary of Sensitive Targets of 2,4-Dichlorophenol – Oral	13
1-11. Summary of Sensitive Targets of 2,4,5-Trichlorophenol – Oral	14
1-12. Summary of Sensitive Targets of 2,4,6-Trichlorophenol – Oral	15
1-13. Summary of Sensitive Targets of 2,3,4,6-Tetrachlorophenol – Oral	16
2-1. Overview of the Number of Studies Examining 2-Chlorophenol Health Effects	23
2-2. Overview of the Number of Studies Examining 4-Chlorophenol Health Effects	24
2-3. Overview of the Number of Studies Examining 2,4-Dichlorophenol Health Effects	25
2-4. Overview of the Number of Studies Examining 2,4,5-Trichlorophenol Health Effects	26
2-5. Overview of the Number of Studies Examining 2,4,6-Trichlorophenol Health Effects	27
2-6. Overview of the Number of Studies Examining 2,3,4,6-Tetrachlorophenol Health Effects	28
2-7. Overview of the Number of Studies Examining Other Chlorophenol Health Effects	29
2-8. Levels of Significant Exposure to Chlorophenols – Inhalation	31
2-9. Levels of Significant Exposure to 2-Chlorophenol – Oral	36
2-10. Levels of Significant Exposure to 4-Chlorophenol – Oral	42
2-11. Levels of Significant Exposure to 2,4-Dichlorophenol – Oral	50
2-12. Levels of Significant Exposure to 2,4,5-Trichlorophenol – Oral	56
2-13. Levels of Significant Exposure to 2,4,6-Trichlorophenol – Oral	61

2-14	. Levels of Significant Exposure to 2,3,4,6-Tetrachlorophenol – Oral	67
2-15	. Levels of Significant Exposure to Other Chlorophenols – Oral	72
5-1.	Number of NPL Sites with Chlorophenols Contamination	167
6-1.	Summary of Existing Health Effects Studies on 2-Chlorophenol By Route and Endpoint	220
6-2.	Summary of Existing Health Effects Studies on 4-Chlorophenol By Route and Endpoint	221
6-3.	Summary of Existing Health Effects Studies on 2,4-Dichlorophenol By Route and Endpoint	222
6-4.	Summary of Existing Health Effects Studies on 2,4,5-Trichlorophenol By Route and Endpoint	223
6-5.	Summary of Existing Health Effects Studies on 2,4,6-Trichlorophenol By Route and Endpoint	224
6-6.	Summary of Existing Health Effects Studies on 2,3,4,6-Trichlorophenol By Route and Endpoint	225
6-7.	Summary of Existing Health Effects Studies on Other Chlorophenols By Route and Endpoint	226

# LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Chlorophenols	
2-1. Levels of Significant Exposure to Chlorophenols – Inhalatio	n
2-2. Levels of Significant Exposure to 2-Chlorophenol – Oral	
2-3. Levels of Significant Exposure to 4-Chlorophenol – Oral	
2-4. Levels of Significant Exposure to 2,4-Dichlorophenol – Ora	
2-5. Levels of Significant Exposure to 2,4,5-Trichlorophenol – C	ral54
2-6. Levels of Significant Exposure to 2,4,6-Trichlorophenol – C	ral57
2-7. Levels of Significant Exposure to 2,3,4,6-Tetrachlorophenol	– Oral64
2-8. Levels of Significant Exposure to Other Chlorophenols – Or	al70
2-9. Levels of Significant Exposure to Chlorophenols – Dermal	
2-10. Comparisons Among Oral LD <sub>50</sub> Values for Chlorophenols	
2-11. Relationship Between Degree of Chlorination and Sympton Exposed by Intraperitoneal Injection	
2-12. Genotoxicity of 2-Chlorophenol In Vitro	
2-13. Genotoxicity of 4-Chlorophenol In Vitro	
2-14. Genotoxicity of 2,4-Dichlorophenol In Vitro	
2-15. Genotoxicity of 2,5- Dichlorophenol In Vitro	
2-16. Genotoxicity of 2,4,5-Trichlorophenol In Vitro	
2-17. Genotoxicity of 2,4,6-Trichlorophenol In Vitro	
2-18. Genotoxicity of Other Chlorophenols In Vitro	
4-1. Chemical Identity of Chlorophenol Compounds	
4-2. Physical and Chemical Properties of Chlorophenol Compour	nds162
5-1. Facilities that Produce, Process, or Use Chlorophenols	
5-2. Releases to the Environment from Facilities that Produce, Pr	ocess, or Use Chlorophenols172
5-3. Degradation of Chlorophenols by Bacteria Adapted to Penta Oxygen Conditions	
5-4. Lowest Limit of Detection Based on Standards	

5-5.	Summary of Environmental Levels of Chlorophenols	185
5-6.	Chlorophenols Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	186
5-7.	Levels of Chlorophenols in Atmosphere of Samples Collected in Winter 2004 in Strasbourg, France	187
5-8.	Geometric Mean and Selected Percentiles of Urinary 2,4-Dichlorophenol Concentrations (in $\mu g/L$ ) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016	194
5-9.	Geometric Mean and Selected Percentiles of Urinary 2,4-Dichlorophenol Concentrations (Creatinine Corrected) (in $\mu$ g/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016	197
5-10	B. Geometric Mean and Selected Percentiles of Urinary 2,5-Dichlorophenol Concentrations (in $\mu g/L$ ) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016	200
5-11	. Geometric Mean and Selected Percentiles of Urinary 2,5-Dichlorophenol Concentrations (Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016	203
5-12	<ul> <li>Geometric Mean and Selected Percentiles of Urinary 2,4,5-Trichlorophenol Concentrations (in μg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010</li> </ul>	206
5-13	. Geometric Mean and Selected Percentiles of Urinary 2,4,5-Trichlorophenol Concentrations (Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010	208
5-14	<ul> <li>Geometric Mean and Selected Percentiles of Urinary 2,4,6-Trichlorophenol Concentrations (in μg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010</li> </ul>	211
5-15	. Geometric Mean and Selected Percentiles of Urinary 2,4,6-Trichlorophenol Concentrations (Creatinine Corrected) (in μg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010	213
5-16	. Urinary Concentrations (µg/L)from 485 Subjects in the GerES V Study	216
6-1.	Ongoing Study of 2,4- and 2,5-Dichlorophenol	234
7-1.	Regulations and Guidelines Applicable to Chlorophenols	235